Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://diegolbfh264876.oneworldwiki.com/7891568/novo_nordisk_s_retatrutide_australia_a_promising_solution_for_obesity_treatment